PI3K-mTOR in Cancer and Cancer Therapy / Cancer Drug Discovery and Development (PDF)
(Sprache: Englisch)
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes...
sofort als Download lieferbar
Printausgabe 164.99 €
eBook (pdf) -7%
153.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „PI3K-mTOR in Cancer and Cancer Therapy / Cancer Drug Discovery and Development (PDF)“
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway's involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.¿
Autoren-Porträt
Nandini Dey, M.S., Ph.D., is a Senior Scientist Head of Cancer Biology, Avera Cancer Institute Center for Precision Oncology. She is also Assistant Professor of the Department of Internal Medicine at The University of South Dakota Sanford School of Medicine. Dey has more than 20 years of experience in translational research and has authored or co-authored more than 80 publications.
Bibliographische Angaben
- 2016, 1st ed. 2016, 294 Seiten, Englisch
- Herausgegeben: Nandini Dey, Pradip De, Brian Leyland-Jones
- Verlag: Springer-Verlag GmbH
- ISBN-10: 3319342118
- ISBN-13: 9783319342115
- Erscheinungsdatum: 10.06.2016
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Größe: 5.47 MB
- Ohne Kopierschutz
- Vorlesefunktion
Sprache:
Englisch
Kommentar zu "PI3K-mTOR in Cancer and Cancer Therapy / Cancer Drug Discovery and Development"
Schreiben Sie einen Kommentar zu "PI3K-mTOR in Cancer and Cancer Therapy / Cancer Drug Discovery and Development".
Kommentar verfassen